AXON: Revenue Surges but Profits Stay Missing
Key Takeaways
- AXON trades at $426, down 52% from its high, with a 284x P/E and near-zero operating margins despite 31% revenue growth.
- Stock-based compensation at 26% of revenue is the hidden cost — Q4 SBC was 70x larger than net income.
- Analysts project $13.64 EPS by FY2028, but that requires margin expansion from 1% to 15-20% with no evidence it has begun.
- The May 2026 earnings report is the next catalyst — any margin improvement could reignite the stock.
Axon Enterprise trades at $426, down 52% from its $886 high — and the numbers explain why. Q4 2025 revenue hit $797 million, up 31% year-over-year, yet net income was just $3 million. That's a 0.4% net margin on a company the market still values at $34 billion.
Insider selling accelerated through March 2026, with directors Jeri Williams and Erika Nardini among those reducing positions. The stock dropped 15% in a single week after Q4 earnings missed EPS estimates by 23%, even as the top line beat. Wall Street's message is clear: growth alone doesn't justify a 284x P/E.
The bull case hinges on Axon's AI and cloud platform eventually converting massive R&D spending into operating leverage. The bear case says stock-based compensation running at 26% of revenue means shareholders are funding employee paydays, not building equity value. Both sides have data on their side.
Valuation: Premium Pricing for Unprofitable Growth
Axon's valuation metrics read like a speculative tech stock, not a $34 billion enterprise. The trailing P/E sits at 284x. Price-to-sales is 57x. EV/EBITDA clocks in at a staggering 831x. For context, the S&P 500 trades around 22x earnings.
Book value per share is $40.33, putting the price-to-book ratio at 14x. <a href="/posts/market-watch-the-great-saas-repricing-salesforce-adobe-and-servicenow-have-lost-290-billion-in-market-value-while-generating-record-free-cash-flow">Free cash flow yield</a> is 0.34% — a metric that <a href="/posts/deep-dive-free-cash-flow-explained-why-it-matters-more-than-earnings">matters more than earnings</a> for growth companies — — meaning investors earn virtually nothing on their capital at today's price. The company carries $1.71 billion in cash ($21.23 per share), but net debt to EBITDA sits at 12.7x, which signals the cash pile isn't as comforting as it appears relative to lean earnings.
Analysts project FY2028 EPS around $13.64, which would bring the forward P/E down to roughly 31x at today's price. That's the crux of the bull case — but it requires the company to execute a profitability ramp that has shown zero evidence of starting.
Earnings: Revenue Acceleration, Margin Stagnation
Full-year 2025 revenue came in around $2.78 billion, a strong growth trajectory. Q4 revenue of $797 million was the peak quarter, with gross margins holding at 57.9%. The problem is everything below the gross profit line.
Operating income for Q4 was just $10 million — a 1.3% margin. For the full year, operating income was essentially breakeven, with Q3 actually posting a $2 million operating loss. R&D expense ran at $134 million in Q4 alone ($625 million annualized), while SG&A hit $317 million.
Q4 EPS of $0.04 diluted fell well short of the $1.17 consensus. Net income for the full year was only $125 million — largely propped up by a $75 million tax benefit in Q2 and $116 million in other income in Q1. Strip those out and the core business barely breaks even.
Financial Health: Cash-Rich but SBC-Heavy
The <a href="/posts/how-to-read-a-balance-sheet-step-by-step">balance sheet</a> has some genuine strengths. Current ratio sits at 2.53 with $1.71 billion in cash. Working capital is a healthy $2.24 billion. Debt-to-equity is a manageable 0.59.
But the stock-based compensation issue dominates. At 26.2% of revenue, Axon is paying a quarter of its top line in stock to employees. That's $209 million in Q4 alone — 70x the company's net income for the quarter. This isn't a rounding error. It's a structural transfer of value from shareholders to employees that traditional earnings metrics understate.
Interest coverage is just 0.35x, meaning operating income barely covers interest expense of $28.8 million per quarter. The cash conversion cycle of 162 days is also concerning for a technology company — capital is tied up for over five months before cycling back. Days sales outstanding of 108 suggests customers take their time paying, which could pressure cash flow as the company scales.
Growth and Competitive Position
Axon's competitive moat in law enforcement technology is real — one of several <a href="/posts/cyber-stocks-rally-as-geopolitical-risk-rewires-tech-spending">defense stocks</a> with genuine pricing power. The TASER franchise, body cameras, and cloud evidence management platform (Axon Evidence) create high switching costs. Once a police department is on the Axon ecosystem, migrating data to a competitor is painful and expensive.
The AI play — Axon's Draft One product that auto-generates police reports from body camera footage — is the growth catalyst Wall Street is pricing in. Management claims it can save officers 30 minutes per incident. At scale, that's a genuine productivity tool with pricing power.
R&D spending of $625 million annually (22.5% of revenue) reflects heavy investment in this AI pipeline. The question is whether the spend converts to margin expansion or just maintains competitive parity. Axon's international expansion also represents a meaningful opportunity — global law enforcement budgets increasingly favor tech-forward solutions, and Axon faces limited competition outside the US. For a different flavor of defense tech risk, compare AeroVironment's drone-first approach.
Forward Outlook: The 2028 Profitability Bet
Analyst consensus points to roughly $5.82 billion in FY2028 revenue — more than doubling from 2025's $2.78 billion. Expected EPS of $13.64 would represent a dramatic shift from today's near-zero profitability.
That trajectory implies operating margins expanding from ~1% to something approaching 15-20% within three years. It requires SBC as a percentage of revenue to decline meaningfully, R&D to stabilize in absolute dollar terms, and revenue growth to continue at 25%+ compounded. All three assumptions are aggressive — a trajectory similar to what Palantir bulls are betting on.
The next earnings report on May 6, 2026 is the immediate catalyst. Any sign of margin expansion — even a couple of percentage points — could reignite the stock. Conversely, another quarter of $800 million revenue with single-digit millions in operating income would validate the skeptics.
Axon sits well below both its 50-day ($502) and 200-day ($645) moving averages, which is technically bearish. The stock has found initial support near $396 (the 52-week low), and the recent bounce to $426 suggests some buying interest at these levels.
Conclusion
Axon Enterprise is a high-quality business with a mediocre <a href="/posts/how-to-read-an-income-statement-line-by-line">income statement</a>. The law enforcement technology moat, AI product pipeline, and 31% revenue growth are real. The 284x P/E, 26% SBC dilution, and near-zero operating margins are also real.
At $426, the stock prices in significant execution risk. Investors who buy here are betting that 2028's projected $13.64 EPS materializes, which means trusting management to deliver a profitability inflection that hasn't started yet. The 52% decline from the high has removed some excess froth, but a forward P/E of 31x on estimates three years out is not a bargain — it's a fair price for perfect execution. Hold if you own it. Wait for margin proof before adding.
Frequently Asked Questions
Sources & References
www.tikr.com
www.trefis.com
www.fool.com
Disclaimer: This content is for informational purposes only and does not constitute financial advice. Consult qualified professionals before making investment decisions.